Optic atrophy with demyelinating disease of CNS
MONDO:0008132Also known as: optic atrophy with demyelinating disease of CNS
14 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase: PHASE2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
MS vision loss mystery: is it scarring or cell death?
Knowledge-focused CompletedThis study looked at 39 people with multiple sclerosis who have chronic vision problems. Researchers used eye exams, scans, and electrical tests to see if the vision loss is caused by nerve scarring (demyelination) or nerve cell death (degeneration). The goal is to better underst…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:45 UTC